An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia [EXTENSION OF 700245233]

Trial Profile

An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia [EXTENSION OF 700245233]

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Burosumab (Primary)
  • Indications X-linked dominant hypophosphataemic rickets
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 15 Sep 2014 Results published in the Media Release and presented at the American Society of Bone and Mineral Research (ASBMR) Annual Meeting.
    • 01 Sep 2014 Status changed from active, no longer recruiting to completed.
    • 30 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top